On August 12, ZAI LAB rose 8.04% in regular trading, trading at 20.3 HKD/share, with turnover of 53.37 million HKD. The stock has gained over three consecutive sessions following its Q2 earnings release on August 6.

On the earnings front, ZAI LAB reported Q2 total revenue of $106.3 million, with net product revenue of $105.8 million, up 11% quarter-over-quarter, exceeding market expectations by approximately $2.5 million. The beat was driven by stable performance of Zejula and continued sales growth of Efgartigimod. Citigroup noted the results reinforce confidence that ZAI LAB's China business can stabilize in H2 and resume meaningful growth next year per management guidance.

On the pipeline side, cervical cancer drug Tidler received NMPA approval, schizophrenia drug Kaijiele issued its first prescription and began commercial ramp, and core pipeline asset Zoci received orphan drug designation from the European Medicines Agency, with upcoming ESMO clinical data expected to provide further catalysts.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)